Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Opthea.
RELATED STOCKHEAD STORIES
Health & Biotech
Dr Boreham’s Crucible: Why CSL is the poster child for most junior drug developers
Health & Biotech
Can the myth hold for Opthea’s scientist CEO?
Health & Biotech
Health might be another overnight success in 2020
Health & Biotech
9 of the most interesting biotech bosses in the game: part 2
News
Trading Places: Here are this week’s substantial holder movements
Health & Biotech
Health: Opthea’s taking its successful anti-AMD drug to a 1,320 patient phase III trial; raises $50m
Health & Biotech
Dr Boreham’s Crucible: Can Phylogica finally make magic happen after nearly 15 years of trying?
Health & Biotech
These are the 22 small cap biotechs closest to bringing a drug to market
Health & Biotech
The life sciences investment wave is building. Here’s how to ride it.
Health & Biotech
Eye health is a growing, multi-billion-dollar market. Which stocks are worth a look?
Experts
On the Radar: Which ASX small caps have the eyeballs and rates from the brokers?
Health & Biotech
Rhythm Biosciences’ cheap, effective cancer test could be a godsend to overburdened medical systems
Health & Biotech
When is the right time for a biotech to try and woo big pharma?
Health & Biotech
How Opthea became a $1 billion stock in a month, and analysts reckon there’s still more to come
News
Trading Places: The stocks small cap fund managers were buying and selling this week
Health & Biotech
This index of biotech stocks is up 782 per cent since the GFC
Health & Biotech